Precigen

Precigen is a biopharmaceutical company focused on developing targeted therapies for diseases with high unmet need, with an emphasis on rare diseases and immuno-oncology. Its lead product is PRGN-2012, a gorilla adenovirus-based immunotherapy for recurrent respiratory papillomatosis (RRP), which the FDA approved in 2025 as PAPZIMEOS. The company also develops gene and cell therapy candidates using its proprietary platform technologies.